It is an ECLIA (Electrochemiluminescence immunoassay) based test for quantitative detection of IgG antibodies against SARS-CoV2 in human serum and plasma samples.
The kit utilizes recombinant protein of SARS COV2 i.e Spike protein for detection of anti-COVID antibodies.
The outcome of the test indicates the concentration of IgG antibodies in the sample (In U/mL).
It is used as an adjunct to COVID-19 RT-PCR tests to aid in clinical assessment and not for diagnosis.
Individuals typically begin to develop antibodies 1-3 weeks after symptoms begin, so this test will be usually used about 14-21 days following the start of symptoms.